News
MESO
3.670
-0.54%
-0.020
Mesoblast Limited's (ASX:MSB) Shift From Loss To Profit
We feel now is a pretty good time to analyse Mesoblast Limited's ( ASX:MSB ) business as it appears the company may be...
Simply Wall St. · 2d ago
Why Leslie's Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 4d ago
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
Benzinga · 4d ago
Mesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease
Benzinga · 11/23 14:38
Reported Late Tuesday, Mesoblast Announces Top-Line Long-Term Survival Results For Remestemcel-L From Its Pivotal Phase 3 Trial Through 4-Years In Children With Steroid-Refractory Acute Graft vs Host Disease
Benzinga · 11/23 06:05
Mesoblast Q1 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.50M Miss $3.47M Estimate
Benzinga · 11/23 05:51
Mesoblast Says Graft-Versus-Host Disease Therapy Showed Patient Survival Through Four Years in Phase 3 Trial
Mesoblast Says Graft-Versus-Host Disease Therapy Showed Patient Survival Through Four Years in Phase 3 Trial
MT Newswires · 11/23 04:55
Mesoblast's Fiscal Q1 Loss Narrows, Revenue Declines
Mesoblast's Fiscal Q1 Loss Narrows, Revenue Declines
MT Newswires · 11/23 04:04
Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children or adults w...
GlobeNewswire · 11/22 23:32
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L These long-term survival outcomes are a cornerstone of the BLA resubmission to FDA for approval of reme...
GlobeNewswire · 11/22 23:01
Mesoblast reports operational and financial highlights for Q3
Seekingalpha · 10/31 14:27
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Benzinga · 10/04 07:24
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Benzinga · 10/03 16:27
Mesoblast Submits New Information to US FDA on Items in Complete Response Letter to Biologics License Application for Remestemcel-L
Mesoblast Submits New Information to US FDA on Items in Complete Response Letter to Biologics License Application for Remestemcel-L
MT Newswires · 10/03 04:15
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
Upgrades
Benzinga · 09/06 14:09
Piper Sandler Initiates Coverage On Mesoblast with Overweight Rating, Announces Price Target of $7
Piper Sandler analyst Edward Tenthoff initiates coverage on Mesoblast (NASDAQ:MESO) with a Overweight rating and announces Price Target of $7.
Benzinga · 09/06 10:42
Piper Sandler Starts Mesoblast at Overweight With $7 Price Target
Piper Sandler Starts Mesoblast at Overweight With $7 Price Target
MT Newswires · 09/06 07:03
Mesoblast GAAP EPS of -$0.14, revenue of $10.21M
Mesoblast press release (NASDAQ:<a href="https...
Seekingalpha · 08/31 09:16
Mesoblast's Fiscal 2022 Loss Narrows, Revenue Rises
Mesoblast's Fiscal 2022 Loss Narrows, Revenue Rises
MT Newswires · 08/31 03:55
Jane Bell Joins Mesoblast Board
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of Directors. Ms Bell is a banking ...
GlobeNewswire · 08/18 11:00
More
Webull provides a variety of real-time MESO stock news. You can receive the latest news about Mesoblast through multiple platforms. This information may help you make smarter investment decisions.
About MESO
Mesoblast Limited is an Australia-based company that is engaged in the development of regenerative medicine products. The Company’s primary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It has applied its mesenchymal lineage cell technology platform to the allogeneic cellular medicines portfolio in the industry. Its technology addresses multiple inflammatory conditions with unmet medical needs. The Company’s portfolio of Phase III product candidates comprises remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD), as well as for the treatment of moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection, Revascor for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s subsidiaries include Mesoblast, Inc., Mesoblast International Sarl, Mesoblast Australia Pty Ltd, Mesoblast UK Ltd and BeiCell Ltd.